iRadimed Corporation (NASDAQ:IRMD) Receives Consensus Rating of “Buy” from Analysts

Shares of iRadimed Corporation (NASDAQ:IRMD) have been assigned an average recommendation of “Buy” from the five analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $120.00.

Several equities analysts recently commented on IRMD shares. Weiss Ratings lowered iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, May 20th. Freedom Capital raised iRadimed to a “strong-buy” rating in a report on Thursday, April 2nd.

iRadimed Stock Up 2.1%

NASDAQ IRMD opened at $93.62 on Thursday. iRadimed has a 52 week low of $55.11 and a 52 week high of $107.90. The stock has a market capitalization of $1.20 billion, a PE ratio of 51.16 and a beta of 0.90. The firm has a 50 day moving average of $92.79 and a two-hundred day moving average of $95.93.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings data on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.03. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. The business had revenue of $21.98 million for the quarter, compared to analyst estimates of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. On average, equities research analysts expect that iRadimed will post 1.52 earnings per share for the current fiscal year.

iRadimed Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 29th. Stockholders of record on Friday, May 15th were issued a $0.20 dividend. The ex-dividend date was Friday, May 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. iRadimed’s dividend payout ratio is presently 43.72%.

Insider Buying and Selling at iRadimed

In related news, CEO Roger E. Susi sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $90.60, for a total transaction of $226,500.00. Following the completion of the sale, the chief executive officer owned 2,162,500 shares in the company, valued at $195,922,500. The trade was a 0.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 32,500 shares of company stock worth $2,864,903. 34.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On iRadimed

Hedge funds have recently added to or reduced their stakes in the stock. Tudor Investment Corp ET AL acquired a new position in iRadimed in the third quarter valued at $666,000. SG Americas Securities LLC grew its holdings in shares of iRadimed by 88.6% during the fourth quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider’s stock worth $6,848,000 after purchasing an additional 33,072 shares during the last quarter. Baader Bank Aktiengesellschaft acquired a new stake in shares of iRadimed during the fourth quarter worth about $595,000. RFG Advisory LLC acquired a new stake in shares of iRadimed during the fourth quarter worth about $1,594,000. Finally, Bridge City Capital LLC lifted its holdings in shares of iRadimed by 19.4% in the 4th quarter. Bridge City Capital LLC now owns 70,854 shares of the medical equipment provider’s stock valued at $6,893,000 after purchasing an additional 11,509 shares during the last quarter. 92.34% of the stock is currently owned by hedge funds and other institutional investors.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.